neoadjuvant treatment

Phase 2Small molecule

neoadjuvant treatment is one of 234 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

233

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Intrahepatic CholangiocarcinomaActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Physical ActivityActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Prostate CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Intrahepatic CholangiocarcinomaPhase 2

Active, not recruiting

Neuroendocrine CarcinomaPhase 2

Active, not recruiting

Physical ActivityPreclinical

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

neoadjuvant treatment

SShanghai Zhongshan Hospital

Phase 2

1 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Zinecard

CChildren's Oncology Group

Preclinical

2 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Intrahepatic Cholangiocarcinoma

NCT04669496

N/AActive, not recruiting

Physical Activity

NCT06190600

Q4 2028

Recruiting

Esophageal Squamous Cell Carcinoma

NCT05740995

Q1 2031

Phase 2Recruiting

Neuroendocrine Carcinoma

NCT04268121

Q4 2033

Not yet recruiting

Breast Cancer

NCT07475923

Clinical

Trials by Indication[1]

Intrahepatic Cholangiocarcinoma2 trials

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT04506281·128 enrolled

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Active, not recruiting·SShanghai Zhongshan Hospital·Phase 2/3·NCT04669496·178 enrolled

Adenocarcinoma1 trial

Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT03631615·36 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Recruiting·SShanghai Zhongshan Hospital··NCT05740995·40 enrolled

Neuroendocrine Carcinoma1 trial

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04268121·78 enrolled

Prostate Cancer1 trial

A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT05574712

3 more indications

Pancreatic Cancer1 trial

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Completed·SSeoul National University Hospital··NCT06129812·1,132 enrolled

Breast Cancer1 trial

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

Not yet recruiting·MM.D. Anderson Cancer Center··NCT07475923·300 enrolled

Physical Activity1 trial

Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy

Active, not recruiting·TThe Greater Poland Cancer Centre·N/A·NCT06190600·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for neoadjuvant treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — neoadjuvant treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for neoadjuvant treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Zhongshan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Zhongshan Hospital

neoadjuvant treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Q1 2031

Q4 2033

Trials by Indication[1]

Intrahepatic Cholangiocarcinoma2 trials

Adenocarcinoma1 trial

Esophageal Squamous Cell Carcinoma1 trial

Neuroendocrine Carcinoma1 trial

Prostate Cancer1 trial

Pancreatic Cancer1 trial

Breast Cancer1 trial

Physical Activity1 trial

References

Drug Info

Quick Facts

Related News